Utilizing Plasma Circulating Tumor DNA Sequencing for Precision Medicine in the Management of Solid Cancers

다국어 초록 (Multilingual Abstract)

Plasma circulating tumor DNA (ctDNA) sequencing has demonstrated clinical utility for tumor molecular profiling at initial diagnosis or tumor progression in advanced solid cancers and is being rapidly incorporated into the clinical practice guidelines, including non–small cell lung and breast cancer. Despite relatively low sensitivity, plasma ctDNA sequencing has several advantages over tissue-based assays, including ease of sampling, rapid turnaround time, repeatability, and the ability to overcome spatial heterogeneity, which makes it ideal for investigating acquired resistance and monitoring tumor evolution and dynamics. With technological advancement and declining costs, the clinical application of plasma ctDNA is expanding, and numerous ongoing clinical trials are examining its potential to guide the management of advanced, localized, and even preclinical cancers of various tumor types. The ability of plasma ctDNA analysis to detect minimal residual disease following curative treatment in the absence of clinical disease is among its most promising attributes. Plasma ctDNA sequencing can also facilitate the conduct of clinical trials and drug development, particularly in immunotherapy. In order to incorporate plasma ctDNA sequencing for clinical decision-making, it is important to understand the preanalytical and analytical factors that may affect its sensitivity and reliability.

참고문헌 (Reference)

1 Powles T, "ctDNA guiding adjuvant immunotherapy in urothelial carcinoma" 595 : 432-437, 2021

2 Dasari A, "ctDNA applications and integration in colorectal cancer : an NCI Colon and Rectal-Anal Task Forces whitepaper" 17 : 757-770, 2020

3 Abbosh C, "ctDNA : an emerging neoadjuvant biomarker in resectable solid tumors" 18 : e1003771-, 2021

4 Wang Y, "Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer : a prospective cohort study" 18 : e1003741-, 2021

5 Snyder A, "Use of circulating tumor DNA for cancer immunotherapy" 25 : 6909-6915, 2019

6 Lee J, "Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment : the VIKTORY Umbrella Trial" 9 : 1388-1405, 2019

7 Xiao W, "Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing" 39 : 1141-1150, 2021

8 Tafazzoli A, "The potential value-based price of a multi-cancer early detection genomic blood test to complement current single cancer screening in the USA" 40 : 1107-1117, 2022

9 Henriksen TV, "The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA" 14 : 1670-1679, 2020

10 Manca P, "The added value of baseline circulating tumor DNA profiling in patients with molecularly hyperselected, left-sided metastatic colorectal cancer" 27 : 2505-2514, 2021

11 Berlanga P, "The European MAPPYACTS Trial : precision medicine program in pediatric and adolescent patients with recurrent malignancies" 12 : 1266-1281, 2022

12 Folprecht G, "The CIRCULATE trial : circulating tumor DNA based decision for adjuvant treatment in colon cancer stage II evaluation(AIO-KRK-0217)" 21 : 170-174, 2022

13 Elazezy M, "Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management" 16 : 370-378, 2018

14 Bidard FC, "Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy(PADA-1) : a randomised, open-label, multicentre, phase 3 trial" 23 : 1367-1377, 2022

15 Conforti F, "Surrogacy of pathologic complete response in trials of neoadjuvant therapy for early breast cancer : critical analysis of strengths, weaknesses, and misinterpretations" 8 : 1668-1675, 2022

16 Chakravarty D, "Somatic genomic testing in patients with metastatic or advanced cancer : ASCO provisional clinical opinion" 40 : 1231-1258, 2022

17 Parikh AR, "Serial ctDNA monitoring to predict response to systemic therapy in metastatic gastrointestinal cancers" 26 : 1877-1885, 2020

18 Tie J, "Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer : a prospective biomarker study" 68 : 663-671, 2019

19 Shen SY, "Sensitive tumour detection and classification using plasma cell-free DNA methylomes" 563 : 579-583, 2018

20 Liu MC, "Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA" 31 : 745-759, 2020

21 Velimirovic M, "Rising circulating tumor DNA as a molecular biomarker of early disease progression in metastatic breast cancer" 4 : 1246-1262, 2020

22 Turner NC, "Results of the c-TRAK TN trial : a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate-and high-risk early-stage triple-negative breast cancer" 34 : 200-211, 2023

23 Wo JY, "Results and molecular correlates from a pilot study of neoadjuvant induction FOLFIRINOX followed by chemoradiation and surgery for gastroesophageal adenocarcinomas" 27 : 6343-6353, 2021

24 Liu W, "Response prediction and risk stratification of patients with rectal cancer after neoadjuvant therapy through an analysis of circulating tumour DNA" 78 : 103945-, 2022

25 Kruger S, "Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer" 29 : 2348-2355, 2018

26 Markus H, "Refined characterization of circulating tumor DNA through biological feature integration" 12 : 1928-, 2022

27 Mosele F, "Recommendations for the use of next-generation sequencing(NGS)for patients with metastatic cancers : a report from the ESMO Precision Medicine Working Group" 31 : 1491-1505, 2020

28 윤신교 ; 김미소 ; 홍용상 ; 김한상 ; 김승태 ; 김지훈 ; 윤홍석 ; 유창훈 ; 안희경 ; 김효송 ; 이인희 ; 김인호 ; 박인근 ; 정재호 ; 천재경 ; 김진원 ; 윤지나 ; 임선민 ; 차용준 ; 장세진 ; 장대영 ; 김태원 ; 강진형 ; 김지현, "Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group" 대한암학회 54 (54): 1-9, 2022

29 Cremolini C, "Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan : a phase 2 single-arm clinical trial" 5 : 343-350, 2019

30 Nakajima H, "REMARRY and PURSUIT trials : liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor(EGFR)therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer" 21 : 674-, 2021

31 Bachet JB, "RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer : the AGEO RASANC prospective multicenter study" 29 : 1211-1219, 2018

32 van Helden EJ, "RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer" 13 : 2361-2374, 2019

33 Zhang Q, "Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade" 10 : 1842-1853, 2020

34 Cabalag CS, "Potential clinical utility of a targeted circulating tumor DNA assay in esophageal adenocarcinoma" 276 : e120-6, 2022

35 Wang Z, "Plasma-based microsatellite instability detection strategy to guide immune checkpoint blockade treatment" 8 : e001297-, 2020

36 Vidal J, "Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients" 28 : 1325-1332, 2017

37 McDonald BR, "Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer" 11 : eaax7392-, 2019

38 Bratman SV, "Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab" 1 : 873-881, 2020

39 Zhou Q, "Persistence of ctDNA in patients with breast cancer during neoadjuvant treatment is a significant predictor of poor tumor response" 28 : 697-707, 2022

40 Zhang Y, "Pan-cancer circulating tumor DNA detection in over 10, 000 Chinese patients" 12 : 11-, 2021

41 Strickler JH, "PULSE : a randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer(mCRC)" 39 (39): TPS143-, 2021

42 Borcoman E, "Novel patterns of response under immunotherapy" 30 : 385-396, 2019

43 Hackshaw A, "New genomic technologies for multi-cancer early detection : rethinking the scope of cancer screening" 40 : 109-113, 2022

44 Forde PM, "Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer" 386 : 1973-1985, 2022

45 National Comprehensive Cancer Network, "NCCN clinical practice guidelines in oncology. Non-small cell lung cancer. Version 2.2023"

46 National Comprehensive Cancer Network, "NCCN clinical practice guidelines in oncology. Breast cancer. Version 2.2023"

47 Garcia-Murillas I, "Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer" 7 : 302ra133-, 2015

48 Sanz-Garcia E, "Monitoring and adapting cancer treatment using circulating tumor DNA kinetics : current research, opportunities, and challenges" 8 : eabi8618-, 2022

49 Coakley M, "Molecular residual disease and adjuvant trial design in solid tumors" 25 : 6026-6034, 2019

50 Sahin IH, "Minimal residual disease-directed adjuvant therapy for patients with early-stage colon cancer : CIRCULATE-US" 36 : 604-608, 2022

51 Parikh AR, "Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer" 27 : 5586-5594, 2021

52 Heinemann V, "Metastatic colorectal cancer (RAS-wildtype) after response to first-line treatment with FOLFIR plus cetuximab (AIO-KRK-0114). Report No. NCT02934529"

53 Khakoo S, "MRI tumor regression grade and circulating tumor DNA as complementary tools to assess response and guide therapy adaptation in rectal cancer" 26 : 183-192, 2020

54 Parikh AR, "Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers" 25 : 1415-1421, 2019

55 Rolfo C, "Liquid biopsy for advanced NSCLC : a consensus statement From the International Association for the Study of Lung Cancer" 16 : 1647-1662, 2021

56 Wan JC, "Liquid biopsies for residual disease and recurrence" 2 : 1292-1313, 2021

57 Kustanovich A, "Life and death of circulating cell-free DNA" 20 : 1057-1067, 2019

58 Lo YM, "Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma" 60 : 2351-2355, 2000

59 Kasi PM, "Impact of circulating tumor DNA-based detection of molecular residual disease on the conduct and design of clinical trials for solid tumors" 6 : e2100181-, 2022

60 Montagut C, "Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer" 18 : 221-223, 2012

61 Siravegna G, "How liquid biopsies can change clinical practice in oncology" 30 : 1580-1590, 2019

62 Hindson BJ, "High-throughput droplet digital PCR system for absolute quantitation of DNA copy number" 83 : 8604-8610, 2011

63 Razavi P, "High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants" 25 : 1928-1937, 2019

64 Strickler JH, "Genomic landscape of cell-free DNA in patients with colorectal cancer" 8 : 164-173, 2018

65 Lennon AM, "Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention" 369 : eabb9601-, 2020

66 Imai M, "Expert panel consensus recommendations on the use of circulating tumor DNA assays for patients with advanced solid tumors" 113 : 3646-3656, 2022

67 Jamshidi A, "Evaluation of cell-free DNA approaches for multi-cancer early detection" 40 : 1537-1549, 2022

68 Hackshaw A, "Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK" 125 : 1432-1442, 2021

69 Mouliere F, "Enhanced detection of circulating tumor DNA by fragment size analysis" 10 : eaat4921-, 2018

70 Misale S, "Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer" 486 : 532-536, 2012

71 Bando H, "Effects of metastatic sites on circulating tumor DNA in patients with metastatic colorectal cancer" 6 : e2100535-, 2022

72 Ricciuti B, "Early plasma circulating tumor DNA(ctDNA)changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer(NSCLC)" 9 : e001504-, 2021

73 Chaudhuri AA, "Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling" 7 : 1394-1403, 2017

74 Christensen E, "Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma" 37 : 1547-1557, 2019

75 Hrebien S, "Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial" 30 : 945-952, 2019

76 O’Leary B, "Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer" 9 : 896-, 2018

77 Goldberg SB, "Early assessment of lung cancer immunotherapy response via circulating tumor DNA" 24 : 1872-1880, 2018

78 Pascual J, "ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer : a report from the ESMO Precision Medicine Working Group" 33 : 750-768, 2022

79 Kim S, "Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment" 127 : 898-907, 2022

80 Bettegowda C, "Detection of circulating tumor DNA in early-and late-stage human malignancies" 6 : 224ra24-, 2014

81 Beaver JA, "Detection of cancer DNA in plasma of patients with early-stage breast cancer" 20 : 2643-2650, 2014

82 Cohen JD, "Detection and localization of surgically resectable cancers with a multi-analyte blood test" 359 : 926-930, 2018

83 Moding EJ, "Detecting liquid remnants of solid tumors : circulating tumor DNA minimal residual disease" 11 : 2968-2986, 2021

84 Herberts C, "Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer" 608 : 199-208, 2022

85 Stadler JC, "Current and future clinical applications of ctDNA in immuno-oncology" 82 : 349-358, 2022

86 Grasselli J, "Concordance of blood-and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer" 28 : 1294-1301, 2017

87 Siravegna G, "Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients" 21 : 795-801, 2015

88 Nakamura Y, "Clinical validity of plasma-based genotyping for microsatellite instability assessment in advanced GI cancers : SCRUM-Japan GOZILA substudy" 6 : e2100383-, 2022

89 Klein EA, "Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set" 32 : 1167-1177, 2021

90 Zugazagoitia J, "Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping" 30 : 290-296, 2019

91 Leighl NB, "Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer" 25 : 4691-4700, 2019

92 Nakamura Y, "Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer : SCRUM-Japan GI-SCREEN and GOZILA studies" 26 : 1859-1864, 2020

93 Vidal J, "Clinical impact of presurgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer : a biomarker study from the GEMCAD 1402 trial" 27 : 2890-2898, 2021

94 Zivanovic Bujak A, "Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology : a cohort study" 17 : e1003363-, 2020

95 Turner NC, "Circulating tumour DNA analysis to direct therapy in advanced breast cancer(plasmaMATCH) : a multicentre, multicohort, phase 2a, platform trial" 21 : 1296-1308, 2020

96 Nakamura Y, "Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer : a phase 2 trial" 27 : 1899-1903, 2021

97 Sartore-Bianchi A, "Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer : the phase 2 CHRONOS trial" 28 : 1612-1618, 2022

98 Lim Y, "Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR" 11 : 16333-, 2021

99 Li S, "Circulating tumor DNA predicts the response and prognosis in patients with early breast cancer receiving neoadjuvant chemotherapy" 4 : 2020

100 McDuff SG, "Circulating tumor DNA predicts pathologic and clinical outcomes following neoadjuvant chemoradiation and surgery for patients with locally advanced rectal cancer" 5 : 2021

101 Frank MS, "Circulating tumor DNA monitoring reveals molecular progression before radiologic progression in a real-life cohort of patients with advanced non–small cell lung cancer" 2 : 1174-1187, 2022

102 Henriksen TV, "Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences" 28 : 507-517, 2022

103 Magbanua MJ, "Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival" 32 : 229-239, 2021

104 Topham JT, "Circulating tumor DNA identifies diverse landscape of acquired resistance to anti-epidermal growth factor receptor therapy in metastatic colorectal cancer" 41 : 485-496, 2023

105 Schraa SJ, "Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer(MEDOCC-CrEATE) : study protocol for a trial within a cohort study" 20 : 790-, 2020

106 Tie J, "Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases : a prospective cohort study" 18 : e1003620-, 2021

107 Cabel L, "Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy : a proof-of-concept study" 28 : 1996-2001, 2017

108 Tie J, "Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer" 26 : 1715-1722, 2015

109 Lee B, "Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer" 30 : 1472-1478, 2019

110 Sellami D, "Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes : a focus on PI3K inhibitors" 28 : 2882-2887, 2017

111 Tie J, "Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer" 386 : 2261-2272, 2022

112 Tie J, "Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer" 8 : 346ra92-, 2016

113 Cailleux F, "Circulating tumor DNA after neoadjuvant chemotherapy in breast cancer is associated with disease relapse" 6 : e2200148-, 2022

114 Diehl F, "Circulating mutant DNA to assess tumor dynamics" 14 : 985-990, 2008

115 Smith RA, "Cancer screening in the United States, 2019 : a review of current American Cancer Society guidelines and current issues in cancer screening" 69 : 184-210, 2019

116 Taniguchi H, "CIRCULATE-Japan : circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer" 112 : 2915-2920, 2021

117 Moser T, "Bridging biological cfDNA features and machine learning appro-aches" 39 : 285-307, 2023

118 Kim ES, "Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer : the phase 2B-F1RST trial" 28 : 939-945, 2022

119 Schmiegel W, "Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients : concordance of results from circulating tumor DNA and tissue-based RAS testing" 11 : 208-219, 2017

120 Lee WC, "Background and significance of Korean national cancer screening guideline revision" 58 : 274-276, 2015

121 Diehl F, "BEAMing : single-molecule PCR on microparticles in water-in-oil emulsions" 3 : 551-559, 2006

122 Kotaka M, "Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan" 40 (40): 9-, 2022

123 Radovich M, "Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer : preplanned secondary analysis of the BRE12-158 randomized clinical trial" 6 : 1410-1415, 2020

124 Lee JH, "Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies" 4 : 717-721, 2018

125 Corcoran RB, "Application of cell-free DNA analysis to cancer treatment" 379 : 1754-1765, 2018

126 Reinert T, "Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer" 5 : 1124-1131, 2019

127 Huffman BM, "Analysis of circulating tumor DNA to predict risk of recurrence in patients with esophageal and gastric cancers" 6 : e2200420-, 2022

128 Dawson SJ, "Analysis of circulating tumor DNA to monitor metastatic breast cancer" 368 : 1199-1209, 2013

129 Avanzini S, "A mathematical model of ctDNA shedding predicts tumor detection size" 6 : eabc4308-, 2020

130 Han SW, "381P A tumor-informed, hybrid-capture based ctDNA assay for minimal residual disease(MRD)detection in colorectal cancer(CRC)patients after curative surgery" 33 (33): S710-1, 2022